Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05839444
Other study ID # BT/220901/PM/SAT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 27, 2023
Est. completion date September 12, 2023

Study information

Verified date February 2024
Source Vedic Lifesciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical study. Seventy-eight individuals will be screened, and considering a screening failure rate of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either BioPB-01 or Placebo


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date September 12, 2023
Est. primary completion date September 12, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: 1. Participants who are 25 to 55 years of age (inclusive) at the time ofsigning the informed consent form. 2. Participants having good general health (no active or uncontrolled diseases, infections, or conditions). 3. BMI within the range of 24.9 to 34.9 kg/m2 (inclusive). 4. Random blood glucose level <140 mg/dL. 5. Concurrent metformin use is acceptable for indications other than diabetes. (However, the subject and investigator must not change metformin dosing during the three weeks of the study). 6. Non-pregnant and non-lactating females of childbearing potential who agree to use adequate contraception/sexual abstinence throughout the study period. 7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. 8. Individuals with access to a digital device to fill out the questionnaires. Exclusion Criteria: 1. Participant has a history of uncontrolled hypertension (i.e., =150 mmHg systolic and/or =110 mmHg diastolic). 2. Participant with history of post-prandial hypoglycemia (occurring 2-5 hours after food intake) of unknown cause. 3. Abnormal thyroid-stimulating hormone (TSH) levels (<0.4 or > 4.2 µIU/ml). 4. Known case of Type 1 or 2 diabetes. 5. Participant has a history of heart disease and/or cardiovascular disease, kidney disease (dialysis or renal failure), and/or hepatic impairment or disease. 6. Participant has a history of previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the year prior to screening, immune disorder (i.e., HIV/AIDS), or a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit. 7. Received a vaccine for COVID-19 or any other vaccination in the 2 weeks prior to screening or planned during the study period, currentCOVID-19 infections, or currently have the post COVID-19 condition as defined by the World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis). 8. Have a known intolerance, sensitivity, or allergy to any of the study products, their ingredients, or any excipients used in the formulation. 9. Individuals who have a known history of diverticulitis. 10. Have a known intolerance, sensitivity, or allergy to milk or soy. 11. Any condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the study data. 12. Currently taking dietary supplements other than vitamins and minerals. 13. Taking any other prescription medication at the time of randomization that is known to impact blood sugar and or blood sugar metabolism, as per the Principal Investigator's (PI) discretion. 14. History of smoking, alcohol (heavy drinking as defined by NIAAA [National Institute on Alcohol Abuse and Alcoholism], USA), or substance abuse in the 12 months prior to screening. 15. Receipt or use of an investigational product in another research study within 30 days prior to baseline/Visit 2.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
BioPB-01
2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
Placebo
2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner

Locations

Country Name City State
India Lifecare Hospital Nashik Maharashtra
India Aman Hospital and Research Center Vadodara Gujarat

Sponsors (1)

Lead Sponsor Collaborator
Vedic Lifesciences Pvt. Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the safety of 21 days of BioPB-01 administration on The gastrointestinal (GI) health assessed using a modified Gastrointestinal Symptom Questionnaire (GSQ) compared to baseline and placebo Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on The gastrointestinal (GI) health assessed using a modified Gastrointestinal Symptom Questionnaire (GSQ) compared to baseline and placebo Day 14
Primary To evaluate the safety of 21 days of BioPB-01 administration on The gastrointestinal (GI) health assessed using a modified Gastrointestinal Symptom Questionnaire (GSQ) compared to baseline and placebo Day 7
Primary To evaluate the safety of 21 days of BioPB-01 administration on Stool consistency using Bristol stool form scale (BSFS) compared to baseline and placebo.This scale is a 7 point ordinal scale of stool types. The participants will be asked to rate their stool consistency and frequency daily to assess abnormal stools, defined as alteration in the frequency or consistency type 1, 2, 6, or 7. Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Stool consistency using Bristol stool form scale (BSFS) compared to baseline and placebo. The participants will be asked to rate their stool consistency and frequency daily to assess abnormal stools, defined as alteration in the frequency or consistency type 1, 2, 6, or 7. Day 14
Primary To evaluate the safety of 21 days of BioPB-01 administration on Stool consistency using Bristol stool form scale (BSFS) compared to baseline and placebo. The participants will be asked to rate their stool consistency and frequency daily to assess abnormal stools, defined as alteration in the frequency or consistency type 1, 2, 6, or 7. Day 7
Primary To evaluate the safety of 21 days of BioPB-01 administration on Liver function biomarkers Alanine transaminase (ALT)
Reference range:
Females: 9-52 U/L Males: 21-72 U/L
Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Liver function biomarkers Aspartate aminotransferase (AST)
Reference range:
Females: 14-36 U/L Males: 17-59 U/L
Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Renal function biomarker blood urea nitrogen (BUN) - Female: 7-17 mg/dL or 2.5-6.1 mmol/L Male: 9-20 mg/dL or 3.2-7.1 mmol/L Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Renal function biomarker Creatinine Reference range: Female: 0.52-1.04 mg/dL or 46-92 µmol/L Male: 0.66-1.25 mg/dL or 58-110 µmol/L Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Serum electrolytes (sodium) : 137-145 mmol/L Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Serum electrolytes (potassium): 3.5-5.1 mmol/L Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Vitals - Blood pressure : Both Systolic and Diastolic pressure will be measured Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on Vitals - Pulse rate Day 21
Primary To evaluate the safety of 21 days of BioPB-01 administration on The number and percentage of participants having adverse product reaction (as per CTCAE V5.0) Throughout the study (an average of 21 days)
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing the metabolic health As assessed by the serum lipid profile (Triglycerides (TG), Total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) level from Baseline Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing The insulin sensitivity as assessed by HOMA-IR from baseline Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing The post-prandial insulin response by net incremental area-under-the-curve (AUC) for post-prandial glucose and insulin (30, 60, 90, and 120 min. after standardised meal) from baseline. Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Inflammation by serum C-reactive protein (CRP) level from Baseline Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Satiety using the Appetite/Satiety - using Visual Analog Scale (VAS) from Baseline.
The scale comprises of 4 main domains: 1) Hunger, 2) Fullness after meals, 3) Thoughts of food, 4) Cravings. The appetite will be analysed based on these four domains on a 100 mm VAS. Reduction in scores as compared to day 0 and placebo will indicate improvement in the appetite/satiety and efficacy of the IP on the appetite/satiety.
Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Body weight from baseline. Day 21
Secondary To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Fecal short chain fatty acids (SCFA) Namely acetate, propionate, and butyrate from Baseline. The samples will be analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS). Day 21
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A